Role of GSTP1 Ile105Val and XRCC1 Arg194Trp, Arg280His and Arg399Gln gene polymorphisms in the clinical outcome of advanced non-small cell lung cancer

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 11, 2015, Pages 14909-14916

  Zhao, Ruigang ^a,b,c   Chen, Gang ^a,b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c Inner Mongolia Autonomous Region   (China)

Author keywords

Arg280His; Arg399Gln; Clinical outcome; GSTP1 Ile105Val; NSCLC; XRCC1 Arg194Trp

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DNA BINDING PROTEIN; GLUTATHIONE TRANSFERASE P1; GSTP1 PROTEIN, HUMAN; X-RAY REPAIR CROSS COMPLEMENTING PROTEIN 1;

ADULT; AGED; FEMALE; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; KAPLAN MEIER METHOD; LUNG TUMOR; MALE; MIDDLE AGED; MORTALITY; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DNA-BINDING PROTEINS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUTATHIONE S-TRANSFERASE PI; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME;

EID: 85013477738     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. International Agency for Research on Cancer. Lung Cancer. Estimated Incidence, Mortality and Prevalence Worldwide in 2012. 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Access in 2015-08-01
2. Liu XH, Liu ZL, Sun M, Liu J, Wang ZX, De W. The long non-coding RNA HOTAIR indicates a poor prognosis and promotes metastasis in non-small cell lung cancer. BMC Cancer 2013; 13: 464
3. Henley SJ, Richards TB, Underwood JM, Eheman CR, Plescia M, McAfee TA; Centers for Disease Control and Prevention (CDC). Lung cancer incidence trends among men and women-united states, 2005-2009. MMWR Morb Mortal Wkly Rep 2014; 63: 1-5
4. Boyer TD. The glutathione S-transferases: an update. Hepatology 1989; 9: 486-96
5. Lindahl T, Wood RD. Quality control by DNA repair. Science 1999; 286: 1897-905
6. Zhu G, Lippard SJ. Photoaffinity labeling reveals nuclear proteins that uniquely recognize cisplatin-DNA interstrand cross-links. Biochemistry 2009; 48: 4916-25
7. Duffaud F, Therasse P. New guidelines to evaluate the response to treatment in solid tumors. Bull Cancer 2000; 87: 881-886
8. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 1994; 54: 4313-20
9. Tiseo M, Bordi P, Bortesi B, Boni L, Boni C, Baldini E, Grossi F, Recchia F, Zanelli F, Fontanini G, Naldi N, Campanini N, Azzoni C, Bordi C, Ardizzoni A; Bio-FAST trial group. ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. Br J Cancer 2013; 108: 1695-703
10. Booton R, Ward T, Heighway J, Ashcroft L, Morris J, Thatcher N. Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer. J Thorac Oncol 2006; 1: 679-83
11. Djukic TI, Savic-Radojevic AR, Pekmezovic TD, Matic MG, Pljesa-Ercegovac MS, Coric VM, Radic TM, Suvakov SR, Krivic BN, Dragicevic DP, Simic TP. Glutathione S-transferase T1, O1 and O2 polymorphisms are associated with survival in muscle invasive bladder cancer patients. PLoS One 2013; 8: e74724
12. Kap EJ, Richter S, Rudolph A, Jansen L, Ulrich A, Hoffmeister M, Ulrich CM, Brenner H, Chang-Claude J. Genetic variants in the glutathione S-transferase genes and survival in colorectal cancer patients after chemotherapy and differences according to treatment with oxaliplatin. Pharmacogenet Genomics 2014; 24: 340-7
13. Goricar K, Kovac V, Jazbec J, Zakotnik B, Lamovec J, Dolžan V. Genetic variability of DNA repair mechanisms and glutathione-S-transferase genes influences treatment outcome in osteosarcoma. Cancer Epidemiol 2015; 39: 182-8
14. Deng JH, Deng J, Shi DH, Ouyang XN, Niu PG. Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients. Clin Transl Oncol 2015; 17: 720-6
15. Han B, Guo Z, Ma Y, Kang S, Wang Y, Wei Q, Wu X. Association of GSTP1 and XRCC1 gene polymorphisms with clinical outcome of advanced non-small cell lung cancer patients with cisplatin-based chemotherapy. Int J Clin Exp Pathol 2015; 8: 4113-9
16. Zhou L, Huang A, Zhang D, Yao J, Zhang Y, Li X. Genetic variability of glutathione S-transferases influences treatment outcome of breast cancer. Tumour Biol 2015; 36: 5925-9
17. Lv H, Han T, Shi X, Yao Y, Yao Y, Qiu W, Yue L, Liang J. Genetic polymorphism of GSTP1 and ERCC1 correlated with response to platinumbased chemotherapy in non-small cell lung cancer. Med Oncol 2014; 31: 86
18. Ke HG, Li J, Shen Y, You QS, Yan Y, Dong HX, Liu JH, Shen ZY. Prognostic significance of GSTP1, XRCC1 and XRCC3 polymorphisms in nonsmall cell lung cancer patients. Asian Pac J Cancer Prev 2012; 13: 4413-6
19. Lu C, Spitz MR, Zhao H, Dong Q, Truong M, Chang JY, Blumenschein GR Jr, Hong WK, Wu X. Association between glutathione Stransferase pi polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma. Cancer 2006; 106: 441-7
20. Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, Georgoulias V, Mavroudis D. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer 2009; 10: 118-23
21. Joerger M, Burgers JA, Baas P, Doodeman VD, Smits PH, Jansen RS, Vainchtein LD, Rosing H, Huitema AD, Beijnen JH, Schellens JH. Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine. Cancer Chemother Pharmacol 2012; 69: 25-33
22. Au WW, Salama SA, Sierra-Torres CH. Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Perspect 2003; 111: 1843-50
23. Yang Z, Zhao J. Effect of APE1 and XRCC1 gene polymorphism on susceptibility to hepatocellular carcinoma and sensitivity to cisplatin. Int J Clin Exp Med 2015; 8: 9931-6
24. Sullivan I, Salazar J, Majem M, Pallarés C, Del Río E, Páez D, Baiget M, Barnadas A. Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Lett 2014; 353: 160-6
25. Wu H, Xu C, Chen G, Wang J. X-ray repair crosscomplementing 1 polymorphism and prognosis of platinum-based chemotherapy in gastric and colorectal cancer: a meta-analysis. J Gastroenterol Hepatol 2014; 29: 926-33
26. Li Y, Huang XE, Jin GF, Shen HB, Xu L. Lack of any relationship between chemotherapy toxicity in non-small cell lung cancer cases and polymorphisms in XRCC1 codon 399 or XPD codon 751. Asian Pac J Cancer Prev 2011; 12: 739-42
27. Lee SY, Kang HG, Yoo SS, Kang YR, Choi YY, Lee WK, Choi JE, Jeon HS, Shin KM, Oh IJ, Kim KS, Lee J, Cha SI, Kim CH, Kim YC, Park JY. Polymorphisms in DNA repair and apoptosisrelated genes and clinical outcomes of patients with non-small cell lung cancer treated with first-line paclitaxel-cisplatin chemotherapy. Lung Cancer 2013; 82: 330-9